Kodama Catheter Recall Issued Due To Risk Broken Pieces May Flush Into Patient Arteries

Federal health officials have announced a Class I recall for certain ultrasound catheters, after discovering pieces of the tubing may break free while in use, causing material to enter into a patient’s artery.

The FDA announced the Kodama catheter recall on March 17, indicating the O-ring housing tubing may become damaged and break during use, increasing the risk of rubber material causing a vessel blockage, which could cause serious adverse health consequences, including death.

The recall impacts certain ACIST Kodama Intravascular Ultrasound Catheters, which use high-frequency sound waves to view the inside of an artery. The devices are inserted through an artery in the leg, and guided to an area of the body for health care providers to view.

Sports-Betting-Addiction-Lawsuits
Sports-Betting-Addiction-Lawsuits

According to the recall notice, the O-ring housing tubing may squeeze and damage the O-ring, allowing it to break and flush through a patients arteries. FDA officials are warning that in this event patients could suffer a blood vessel blockage, heart attack, heart arrhythmia, or stroke.

Patients with certain pre-existing conditions, such as improperly functioning heart ventricles, are at an increased risk of series injury or death in the event of a sudden blockage of blood flow.

On January 22, manufacturing firm ACIST Medical Systems, released an Urgent Medical Device Recall letter instructing healthcare facilities to remove all potentially defective Kodama HD-IVUS Catheters from their inventory.

Specifically, the recall impacts Kodama Intravascular Ultrasound Catheters manufactured by ACIST Medical Systems and distributed to medical facilities across the nation between November 10, 2020 and January 14, 2021. The recalled products contain lot numbers 00233370, 00233371, 00233372, 00233373, or 00233385.

The recall instructs all healthcare facilities to record the quantities of the products in their inventory and to return the recall notice letter along with the completed Recall Response Form for information on how to arrange product returns.

While no injuries or adverse reports have been reported to date, the FDA has classified this action as a Class I recall, indicating it is the most serious of its kind, and that use of the recalled catheters may result in serious adverse health consequences or death.

Written by: Russell Maas

Managing Editor & Senior Legal Journalist

Russell Maas is a paralegal and the Managing Editor of AboutLawsuits.com, where he has reported on mass tort litigation, medical recalls, and consumer safety issues since 2010. He brings legal experience from one of the nation’s leading personal injury law firms and oversees the site’s editorial strategy, including SEO and content development.




0 Comments


This field is for validation purposes and should be left unchanged.

Share Your Comments

This field is hidden when viewing the form
I authorize the above comments be posted on this page
Post Comment
Weekly Digest Opt-In

Want your comments reviewed by a lawyer?

To have an attorney review your comments and contact you about a potential case, provide your contact information below. This will not be published.

NOTE: Providing information for review by an attorney does not form an attorney-client relationship.

MORE TOP STORIES

A new lawsuit against Roblox alleges that the platform’s inadequate safety measures enabled multiple sexual predators to exploit a five-year-old girl.
Breast mesh implants promoted as internal bras are now under scrutiny, following studies and FDA warnings linking the devices to infections, implant loss, and surgical failure. Lawsuits are being investigated for women who suffered complications after reconstruction or augmentation procedures involving products like GalaFLEX, Phasix, Strattice, and AlloDerm.
Dupixent users are coming forward with accounts of devastating cancer diagnoses, saying the popular eczema drug masked early warning signs of cutaneous T-cell lymphoma. As the FDA investigates and the first lawsuit is filed, researchers warn Dupixent may unmask or accelerate hidden cancers, raising urgent questions about its long-term safety.